Rahul Banerjee: Fascinating Multiple Myeloma results of MajesTEC-1 in BCMA-exposed patients
Rahul Banerjee shared a post by Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, on X adding:
“‘Prior to starting teclistamab, baseline BCMA expression and immune characteristics were unaffected by prior anti-BCMA treatment.’
Fascinating Blood Journal results of MajesTEC-1 in BCMA-exposed patients.
Congrats Touzeau, Amrita Krishnan, Saad Z. Usmani, Nizar Jacques Bahlis, Al Garfall et al.”
Quoting Robert Z. Orlowski’s post:
“Myeloma Paper of the Day:
Study of teclistamab efficacy and safety in relapsed/refractory myeloma post-BCMA-targeting txs shows good ORR of 52.5% and median PFS 4.5 months with neutropenia, infections, cytokine release syndrome and anemia as main AEs.”
Source: Rahul Banerjee/X and Robert Z. Orlowski/X
Authors: Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K. Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J. Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, and Alfred Garfall.
Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.
